A Look At Teva (NYSE:TEVA) Valuation After EMA Accepts Filing For Monthly Schizophrenia Injection

Teva Pharmaceutical Industries (NYSE:TEVA) just cleared an important regulatory hurdle in Europe, with the European Medicines Agency accepting its application for TEV-749, a once monthly olanzapine injection for adults with schizophrenia.

See our latest analysis for Teva Pharmaceutical Industries.

The latest EMA update lands after a steady run in the stock, with a 30 day share price return of 11.19% and a year to date share price return of 10.08%. The 1 year total shareholder return is 100.88%, pointing to strong longer term momentum despite some recent softness.

If you are looking beyond large pharmaceutical stocks and want other ideas in health related technology, this could be a good moment to review 34 healthcare AI stocks

With the stock up sharply over the past year and trading at a discount to the average analyst price target, the key question now is simple: is there still value left on the table, or is the market already pricing in future growth?

Most Popular Narrative: 15% Undervalued

Based on the most followed narrative, Teva Pharmaceutical Industries' fair value of $40.09 sits above the last close at $34.07, putting the current discount in sharper focus.

Teva's strategic focus and rapid execution on expanding its innovative branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.

Read the complete narrative.

Want to see what sits behind that higher margin story and premium earnings multiple? The narrative leans on measured revenue growth, rising profitability, and a richer product mix. The full breakdown shows how those ingredients combine into the $40.09 fair value.

Result: Fair Value of $40.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on a tight set of assumptions, and setbacks in the R&D pipeline or pressure on key branded drugs could quickly challenge that higher earnings profile.

Find out about the key risks to this Teva Pharmaceutical Industries narrative.

Another View: Valuation Looks Rich On P/E

There is a clear tension between the fair value of $40.09 and what the market is paying for each dollar of earnings. At $34.07, Teva Pharmaceutical Industries trades on a P/E of 25.3x versus 14.7x for the wider US Pharmaceuticals industry, 19.6x for peers, and a fair ratio of 21.3x, which points to valuation risk if expectations ease.

For investors who prefer to anchor decisions on earnings multiples rather than cash flow models, that gap raises a simple question: is the potential upside to fair value worth paying well above both the industry and fair ratio benchmarks today, or does it leave less room for error?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between upside potential and valuation risk, this is a good moment to move quickly, review the data yourself, and weigh the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at one stock, you risk missing better fits for your goals, so use the screeners to widen your options and pressure test your thinking.

• Target dependable cash generators by reviewing the 10 dividend fortresses that could help support a steadier income stream in your portfolio.
• Hunt for mispriced opportunities using the 49 high quality undervalued stocks to spot stocks where fundamentals and price look out of sync.
• Strengthen your downside protection by scanning the 67 resilient stocks with low risk scores that focus on resilience when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com